Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs
Treatment of psoriasis associated with human immunodeficiency virus (HIV) infection is challenging due to the high incidence of comorbidities and polypharmacy and the lack of evidence on the efficacy and safety of available drugs in these patients. Therefore, clinical or anecdotal reports provide us...
Saved in:
Main Authors: | Viviana Lora (Author), Dario Graceffa (Author), Monia Di Prete (Author), Carlo Cota (Author) |
---|---|
Format: | Book |
Published: |
PAGEPress Publications,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Annular elastolytic giant cell granuloma after COVID-19 vaccination
by: Viviana Lora, et al.
Published: (2023) -
Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023) -
Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
by: Martina Burlando, et al.
Published: (2021) -
Tildrakizumab in Psoriasis and Beyond
by: Aditya K. Bubna, et al.
Published: (2024) -
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018)